These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Recombinant DNA Technology I. Conference on progress in recombinant DNA technology and applications. Potosi, Missouri, June 3-8, 1990. Ann N Y Acad Sci; 1991 Dec; 646():1-383. PubMed ID: 1687307 [No Abstract] [Full Text] [Related]
23. Biotechnology and culture: the impact of public debates on government regulation in the United States and Denmark. Baark E; Jamison A Technol Soc; 1990; 12(1):27-44. PubMed ID: 11650912 [No Abstract] [Full Text] [Related]
24. [Recombinant strains: their biological properties and the safety measures in working with them]. Vorob'ev AA; Khoroshko NV; Selezneva OIu Vestn Ross Akad Med Nauk; 1993; (2):31-7. PubMed ID: 7688617 [TBL] [Abstract][Full Text] [Related]
25. Biotechnology: are there unique health and safety issues? Sleigh MJ Australas Biotechnol; 1991 Oct; 1(2):104-7. PubMed ID: 1367644 [No Abstract] [Full Text] [Related]
26. Cytokine expression by recombinant viruses--a new vaccine strategy. Ramshaw IA; Ruby J; Ramsay A Trends Biotechnol; 1992 Dec; 10(12):424-6. PubMed ID: 1369132 [No Abstract] [Full Text] [Related]
28. Biotechnology: low risks at a premium. Beardsley T Nature; 1984 Apr 12-18; 308(5960):579. PubMed ID: 6709067 [No Abstract] [Full Text] [Related]
29. What biotechnology has to offer vaccine development. Fields BN; Chanock RM Rev Infect Dis; 1989; 11 Suppl 3():S519-23. PubMed ID: 2669095 [TBL] [Abstract][Full Text] [Related]
30. Recombinant DNA Biotechnology III: The Integration of Biological and Engineering Sciences. Proceedings of a conference. Deauville, France, October 16-21, 1994. Ann N Y Acad Sci; 1996 May; 782():1-569. PubMed ID: 9729211 [No Abstract] [Full Text] [Related]
33. Perception of risks and benefits of in vitro fertilization, genetic engineering and biotechnology. Macer DR Soc Sci Med; 1994 Jan; 38(1):23-33. PubMed ID: 8146712 [TBL] [Abstract][Full Text] [Related]
35. Asilomar revisited: lessons for today? Barinaga M Science; 2000 Mar; 287(5458):1584-5. PubMed ID: 10766605 [No Abstract] [Full Text] [Related]
36. Biotechnology and genetic engineering in the new drug development. Part I. DNA technology and recombinant proteins. Stryjewska A; Kiepura K; Librowski T; Lochyński S Pharmacol Rep; 2013; 65(5):1075-85. PubMed ID: 24399704 [TBL] [Abstract][Full Text] [Related]
38. Assuring the safety and efficacy of DNA vaccines. Griffiths E Ann N Y Acad Sci; 1995 Nov; 772():164-9. PubMed ID: 8546389 [No Abstract] [Full Text] [Related]
39. An overview of biotechnology. Demain AL Occup Med; 1991; 6(2):157-68. PubMed ID: 2047970 [TBL] [Abstract][Full Text] [Related]
40. Production and analysis of proteins by recombinant DNA technology. Pestka S Bioprocess Technol; 1990; 7():235-65. PubMed ID: 1366823 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]